|
Monday 18th September 2023 |
Text too small? |
TruScreen Group Limited (NZX/ASX:TRU) is pleased to report that the Dr Sulaiman Al-Habib Medical Group, has installed the first tranche of four TruScreen devices for commercial use, for the screening of cervical cancer in Saudi Arabia.
Dr Sulaiman Al-Habib Medical Group (DSAMG) is the largest private hospital network in the Middle East. The adoption of TruScreen’s screening technology by DSAMG private hospitals will be important reference sites for further market access in neighbouring Middle Eastern nations.
This installation follows from the previously announced successful completion of the clinical evaluation by DSAMG network, followed by a successful tender by BettaLife Trading FZC (BettaLife) (Truescreen’s distributor in the Middle East).
The excellent clinical results of the evaluation were announced previously: see link
https://www.nzx.com/announcements/408275
TruScreen’s CEO, Dr Beata Edling said:
“I am very pleased that the Dr Sulaiman Al-Habib Medical Group have approved and will use TruScreen technology to advance the screening for cervical cancer in their hospital network.
We congratulate BettaLife, our partner in Saudi Arabia, on reaching this important milestone which will support the expansion of the TruScreen operations in the Middle East.”
This announcement has been approved by the Board.
Ends
Commercial Breakthrough in Saudi Arabia - Commences use of TruScreen Technology
No comments yet
HGH Ltd Results for the 6 months ended 1 February 2026
March 27th Morning Report
CDC investor presentation and guidance update
PFI - Potential Bond Offer by PFI
MCY - Mercury Green Bond offer - interest rate set
March 25th Morning Report
AFT - Chief Financial Officer update
KMD Brands: Response to Stokehouse transaction concept
March 24th Morning Report
MCY - Mercury launches retail Green Bond offer